Sunday, July 09, 2017 7:27:12 PM
Recent DRNK Updates- Stock Repurchase, SS Restructuring, Acquisitions, Distribution Deals, Debt re-negotiation/elimination, New products, No RS in 2017:
(for additional information on NOHO please visit www.nohodrink.com and our full product site at www.imbutek.com and at www.instagram.com/nohodrink, as well as at www.twitter.com/nohodrink
Issuer Stock Repurchase Program
http://ih.advfn.com/p.php?pid=nmona&artic...ymbol=DRNK
The Company intends to activate a stock repurchase program ("Stock Repurchase" pursuant to Rule 10b-18 which allows Issuers to post bids for and purchases of an issuer's common stock by or for an issuer or an "affiliated purchaser" of an issuer. The safe harbor excludes bids and purchases made during certain corporate events such as mergers, tender offers, and distributions that involve the issuer. The safe harbor provides only that certain, specific provisions of the securities laws will not be considered to have been violated solely by reason of the manner, timing, price, or volume of such repurchases, provided the repurchases are made within the limitations of the Rule. The company will disclose all information regarding the common stock the Company has repurchased as it is important and useful to investors to include specific information regarding repurchase activity by issuers and their affiliates.
Cancellation of Class B Preferred Shares
http://ih.advfn.com/p.php?pid=nmona&artic...ymbol=DRNK
NOHO has instructed counsel to cancel all Class B preferred shares. As a result, the insiders will no longer have that mechanism to obtain common stock. It should be further noted that the insiders of NOHO have never converted any shares in this class and therefore have never owned or sold any common stock. The company has directed counsel to further reduce the authorized shares commensurate to this cancellation. Further updates will be provided as developments occur.
NOHO Licences New FDA Formulation and Completes Asset Purchase WITH Greenfield Farms
http://ih.advfn.com/p.php?pid=nmona&artic...ymbol=DRNK
PHOENIX, AZ - June 7, 2017 - InvestorsHub NewsWire - NOHO, Inc. (OTC PINK: DRNK), a Wyoming corporation (the "Company" , announced the following:
FDA Formulation
The Company has executed a licensing agreement with DMR Biologics, LLC, of Schofield, Wisconsin, to acquire the exclusive rights to market and sell its homeopathic, FDA registered drug under the NOHO brand. This new, lipid-based gel formulation is taken via a patented, sublingual (under the tongue) delivery method, contained in a small stick pack. The product offers fast and effective relief from Hangover pain and headache in bypassing the digestive system so it can be absorbed much faster than liquid or pill-based formulas. As a homeopathic medicine, it has no contraindicated drug interactions. The product's effectiveness is confirmed by two Double-blind/Placebo controlled clinical trials. Developed as a drug to treat migraine headaches, NOHO has contracted the exclusive rights to the product in the Hangover market. Most Hangover headaches are migranous in nature and there are numerous cross-over symptoms shared between migraine headaches and Hangovers.
David Mersky, NOHO's CEO stated, "Today, we are announcing that the company has acquired the exclusive rights to an FDA registered medicine that will be manufactured as a new NOHO product for the Hangover market. As an OTC drug, this new formulation will make NOHO the market leader in the Hangover space as the product is backed by two published clinical studies."
The company is in the process of obtaining a National Drug Code number and has secured financing to begin production of the new formulation within 30 days. Labeling and packaging designs will also be underway so that all approvals will be in place when the product is market ready in approximately 90 days. In addition to the formulation being clinically tested with great success, it is well-suited to both the retail and online markets, as it is small and light (a unit dose is 3ml) and can be easily carried by users or shipped in larger quantities at low cost.
"We are currently in negotiations for a large initial purchase order on the new product, which we hope to close while the initial run is in production. This new relationship will open the doors to the retail market and provide immediate revenue to the company. We'll be disclosing more details as we move ahead, but suffice it to say we're really excited by what's ahead for NOHO," said Mersky.
Greenfield Farms (GRAS)
The company, through Cherry Hill Financial, LLC, has completed the Asset Purchase Agreement with Greenfield Farms Food Inc. (OTC PINK: GRAS). Pursuant to the deal, Cherry Hill's membership interest was acquired in exchange for 49% of GRAS' common stock. As the first of a series of anticipated transactions, the model places NOHO in control of the board of directors of the target.
The agreement requires GRAS to divest itself of its prior operations and bring in a new staff of licensed brokers and support personnel to begin marketing its pre-paid life insurance program to employees of staffing companies throughout the country. Ronald Heineman, GRAS' CEO will remain in place and rely on his years of experience in the staffing industry to access nearly 24,000 employees for enrollments.
The insurance program will pair employee bases with target companies under a co-employment relationship and offer employees life insurance as a 401(k) alternative, providing pre-paid coverage for up to three years.
David Mersky, NOHO, Inc.'s CEO, stated, "We have finally put all the pieces together to complete the acquisition of GRAS so we can begin to put the operations in place to start selling policies. It is a highly specialized and niche insurance offering that requires very particular components. We've got the secret sauce."
GRAS' shares will be booked corporately in NOHO's investment account.
No R/S in 2017 CONFIRMED by Management through e-mail and twitter:
Email excerpt:
We're consolidating our websites. All product sales are now on Amazon as well.
As to your other question, management has announced no reverse split in 2017. Thanks for following up.
Twitter post:
https://twitter.com/NOHOdrink/status/865346088886083584
NOHO Signs Letter of Intent for FDA Registered Drug Formulation
http://www.otcmarkets.com/stock/DRNK/news/NOH...64&b=y
PHOENIX, AZ--(Marketwired - Apr 27, 2017) - NOHO, Inc. (OTC PINK: DRNK), a Wyoming corporation (the "Company" , announced the following:
The Company has signed a letter of intent with DMR Biologic, LLC, of Schonfield, Wisconsin, to acquire the rights to market and sell its homeopathic OTC drug registered with the FDA.
This new formulation is taken via a patented, gel-based delivery method contained in a small stick pack. The product is taken sublingually (under the tongue), offering fast and effective relief from Hangover pain and headache. In bypassing the digestive system, the product is absorbed much faster than liquid or pill-based formulas and has no contraindicated drug interactions. The product's effectiveness is confirmed by multiple Double-blind/Placebo controlled clinical trials. Developed as a drug to treat migraine headaches, under the proposed deal, NOHO would have exclusive rights to the product in the Hangover market and register the new brand with the FDA and obtain a National Drug Code number. The proposed terms also include distribution for a re-branded migraine product which NOHO would market and sell through its new distributor, BNG Enterprises.
David Mersky, NOHO's CEO, stated, "In keeping with our strategy of pursuing undervalued assets like our 2oz Shot and Gold can products when we came into NOHO, we have once again found a great opportunity to bring an FDA compliant product to the Hangover market. As an OTC drug, this new formulation will make NOHO the market leader in the Hangover space, as none of the competition has clinically tested data to be able to make specific drug claims." Negotiations also involve NOHO working to re-launch a new iteration of the original migraine drug, called Lipigesic. Mersky continued, "I believe this is a great product that wasn't properly packaged and didn't have the appropriate marketing to support it. The test results are terrific and the migraine market is huge at around 50 million people. We're really good at identifying these hidden gems that require a dust-off and some re-branding. All the time, hard work and cost of the trials and FDA registration is already done."
In addition to the current formulation, the parties are discussing a hemp infused product for NOHO to bring to market. "We have identified a path to infuse Hemp, as a legal food product, into the formula. A Hemp-infused Hangover drug will fly off the shelves through our targeted distribution in smoke shops and vape stores," said NOHO's CEO David Mersky.
DD to the DRNK LOI drug by DMR Biologic, LLC (formerly Puramed Biosc.):
https://www.bizapedia.com/wi/dmr-biologics-llc.html
https://ndclist.com/?s=34331-202-06 (formerly puramed bioscience;
1326 Schofield Avenue, Schofield, WI 54476 - now PMBS; DMR Biologic, LLC http://www.otcmarkets.com/stock/PMBS/profile )
Patent:
http://patft.uspto.gov/netacgi/nph-Parser?Sec...=8,409,637
NOHO Inks Deal for Nationwide Distribution
https://finance.yahoo.com/news/noho-inks-deal...00865.html
PHOENIX, AZ--(Marketwired - Apr 27, 2017) - NOHO, Inc. ( OTC : DRNK ), a Wyoming corporation (the "Company" , announced the following:
The Company is pleased to announce the signing of a national sales and distribution agreement with BNG Enterprises, Inc. ("BNG" , located in Tempe, Arizona (www.bngprodx.com). The agreement provides BNG the exclusive rights to sell the NOHO 2oz Shot throughout its nationwide retail stores as well as online sales through Amazon®.Our NOHO 2oz Shot will now be placed into the BNG sales engine, with the ability to be sold in national chains such as GNC and Vitamin Shoppe, in addition to independent smoke shops, vape shops and health stores. BNG's sales force will be putting the Shot into its national distribution in all major markets with concentration in California, New York and Florida.
Update 4/26/17 A/S reduced
https://wyobiz.wy.gov/Business/FilingDetails....1140218168
see Additional Details ; also, Update Restated Articles
NOHO, Inc. to Freeze Conversions and Negotiates Debt Buyout
https://finance.yahoo.com/news/noho-inc-freez...00170.html
PHOENIX, AZ--(Marketwired - Apr 24, 2017) - NOHO, Inc. ( OTC : DRNK ), a Wyoming corporation (the "Company" , announced the following:
The Company has reached an agreement in principle with its 95% majority convertible note holder for a moratorium on conversions, relating to notes issued after March 7, 2015.
In addition to freezing conversions, the Company will maintain its ability to retire the outstanding notes in cash.
If the notes subject to the freeze are not repurchased by the Company, the parties have agreed to a restriction of stock sales, subject to a lockdown and leakout agreement, which is currently being finalized.
David Mersky, NOHO's CEO, stated, "We have come to terms with our majority note holder to freeze conversions, which puts NOHO in a very strong position moving forward with significant developments underway. This is a strong signal of our majority debt holder's confidence in the long term vision we have for the Company. This agreement is also a big win for our shareholders, as we continue to make changes to reduce the outstanding shares and avoid dilution as a priority moving forward."
(for additional information on NOHO please visit www.nohodrink.com and our full product site at www.imbutek.com and at www.instagram.com/nohodrink, as well as at www.twitter.com/nohodrink
Issuer Stock Repurchase Program
http://ih.advfn.com/p.php?pid=nmona&artic...ymbol=DRNK
The Company intends to activate a stock repurchase program ("Stock Repurchase" pursuant to Rule 10b-18 which allows Issuers to post bids for and purchases of an issuer's common stock by or for an issuer or an "affiliated purchaser" of an issuer. The safe harbor excludes bids and purchases made during certain corporate events such as mergers, tender offers, and distributions that involve the issuer. The safe harbor provides only that certain, specific provisions of the securities laws will not be considered to have been violated solely by reason of the manner, timing, price, or volume of such repurchases, provided the repurchases are made within the limitations of the Rule. The company will disclose all information regarding the common stock the Company has repurchased as it is important and useful to investors to include specific information regarding repurchase activity by issuers and their affiliates.
Cancellation of Class B Preferred Shares
http://ih.advfn.com/p.php?pid=nmona&artic...ymbol=DRNK
NOHO has instructed counsel to cancel all Class B preferred shares. As a result, the insiders will no longer have that mechanism to obtain common stock. It should be further noted that the insiders of NOHO have never converted any shares in this class and therefore have never owned or sold any common stock. The company has directed counsel to further reduce the authorized shares commensurate to this cancellation. Further updates will be provided as developments occur.
NOHO Licences New FDA Formulation and Completes Asset Purchase WITH Greenfield Farms
http://ih.advfn.com/p.php?pid=nmona&artic...ymbol=DRNK
PHOENIX, AZ - June 7, 2017 - InvestorsHub NewsWire - NOHO, Inc. (OTC PINK: DRNK), a Wyoming corporation (the "Company" , announced the following:
FDA Formulation
The Company has executed a licensing agreement with DMR Biologics, LLC, of Schofield, Wisconsin, to acquire the exclusive rights to market and sell its homeopathic, FDA registered drug under the NOHO brand. This new, lipid-based gel formulation is taken via a patented, sublingual (under the tongue) delivery method, contained in a small stick pack. The product offers fast and effective relief from Hangover pain and headache in bypassing the digestive system so it can be absorbed much faster than liquid or pill-based formulas. As a homeopathic medicine, it has no contraindicated drug interactions. The product's effectiveness is confirmed by two Double-blind/Placebo controlled clinical trials. Developed as a drug to treat migraine headaches, NOHO has contracted the exclusive rights to the product in the Hangover market. Most Hangover headaches are migranous in nature and there are numerous cross-over symptoms shared between migraine headaches and Hangovers.
David Mersky, NOHO's CEO stated, "Today, we are announcing that the company has acquired the exclusive rights to an FDA registered medicine that will be manufactured as a new NOHO product for the Hangover market. As an OTC drug, this new formulation will make NOHO the market leader in the Hangover space as the product is backed by two published clinical studies."
The company is in the process of obtaining a National Drug Code number and has secured financing to begin production of the new formulation within 30 days. Labeling and packaging designs will also be underway so that all approvals will be in place when the product is market ready in approximately 90 days. In addition to the formulation being clinically tested with great success, it is well-suited to both the retail and online markets, as it is small and light (a unit dose is 3ml) and can be easily carried by users or shipped in larger quantities at low cost.
"We are currently in negotiations for a large initial purchase order on the new product, which we hope to close while the initial run is in production. This new relationship will open the doors to the retail market and provide immediate revenue to the company. We'll be disclosing more details as we move ahead, but suffice it to say we're really excited by what's ahead for NOHO," said Mersky.
Greenfield Farms (GRAS)
The company, through Cherry Hill Financial, LLC, has completed the Asset Purchase Agreement with Greenfield Farms Food Inc. (OTC PINK: GRAS). Pursuant to the deal, Cherry Hill's membership interest was acquired in exchange for 49% of GRAS' common stock. As the first of a series of anticipated transactions, the model places NOHO in control of the board of directors of the target.
The agreement requires GRAS to divest itself of its prior operations and bring in a new staff of licensed brokers and support personnel to begin marketing its pre-paid life insurance program to employees of staffing companies throughout the country. Ronald Heineman, GRAS' CEO will remain in place and rely on his years of experience in the staffing industry to access nearly 24,000 employees for enrollments.
The insurance program will pair employee bases with target companies under a co-employment relationship and offer employees life insurance as a 401(k) alternative, providing pre-paid coverage for up to three years.
David Mersky, NOHO, Inc.'s CEO, stated, "We have finally put all the pieces together to complete the acquisition of GRAS so we can begin to put the operations in place to start selling policies. It is a highly specialized and niche insurance offering that requires very particular components. We've got the secret sauce."
GRAS' shares will be booked corporately in NOHO's investment account.
No R/S in 2017 CONFIRMED by Management through e-mail and twitter:
Email excerpt:
We're consolidating our websites. All product sales are now on Amazon as well.
As to your other question, management has announced no reverse split in 2017. Thanks for following up.
Twitter post:
https://twitter.com/NOHOdrink/status/865346088886083584
NOHO Signs Letter of Intent for FDA Registered Drug Formulation
http://www.otcmarkets.com/stock/DRNK/news/NOH...64&b=y
PHOENIX, AZ--(Marketwired - Apr 27, 2017) - NOHO, Inc. (OTC PINK: DRNK), a Wyoming corporation (the "Company" , announced the following:
The Company has signed a letter of intent with DMR Biologic, LLC, of Schonfield, Wisconsin, to acquire the rights to market and sell its homeopathic OTC drug registered with the FDA.
This new formulation is taken via a patented, gel-based delivery method contained in a small stick pack. The product is taken sublingually (under the tongue), offering fast and effective relief from Hangover pain and headache. In bypassing the digestive system, the product is absorbed much faster than liquid or pill-based formulas and has no contraindicated drug interactions. The product's effectiveness is confirmed by multiple Double-blind/Placebo controlled clinical trials. Developed as a drug to treat migraine headaches, under the proposed deal, NOHO would have exclusive rights to the product in the Hangover market and register the new brand with the FDA and obtain a National Drug Code number. The proposed terms also include distribution for a re-branded migraine product which NOHO would market and sell through its new distributor, BNG Enterprises.
David Mersky, NOHO's CEO, stated, "In keeping with our strategy of pursuing undervalued assets like our 2oz Shot and Gold can products when we came into NOHO, we have once again found a great opportunity to bring an FDA compliant product to the Hangover market. As an OTC drug, this new formulation will make NOHO the market leader in the Hangover space, as none of the competition has clinically tested data to be able to make specific drug claims." Negotiations also involve NOHO working to re-launch a new iteration of the original migraine drug, called Lipigesic. Mersky continued, "I believe this is a great product that wasn't properly packaged and didn't have the appropriate marketing to support it. The test results are terrific and the migraine market is huge at around 50 million people. We're really good at identifying these hidden gems that require a dust-off and some re-branding. All the time, hard work and cost of the trials and FDA registration is already done."
In addition to the current formulation, the parties are discussing a hemp infused product for NOHO to bring to market. "We have identified a path to infuse Hemp, as a legal food product, into the formula. A Hemp-infused Hangover drug will fly off the shelves through our targeted distribution in smoke shops and vape stores," said NOHO's CEO David Mersky.
DD to the DRNK LOI drug by DMR Biologic, LLC (formerly Puramed Biosc.):
https://www.bizapedia.com/wi/dmr-biologics-llc.html
https://ndclist.com/?s=34331-202-06 (formerly puramed bioscience;
1326 Schofield Avenue, Schofield, WI 54476 - now PMBS; DMR Biologic, LLC http://www.otcmarkets.com/stock/PMBS/profile )
Patent:
http://patft.uspto.gov/netacgi/nph-Parser?Sec...=8,409,637
NOHO Inks Deal for Nationwide Distribution
https://finance.yahoo.com/news/noho-inks-deal...00865.html
PHOENIX, AZ--(Marketwired - Apr 27, 2017) - NOHO, Inc. ( OTC : DRNK ), a Wyoming corporation (the "Company" , announced the following:
The Company is pleased to announce the signing of a national sales and distribution agreement with BNG Enterprises, Inc. ("BNG" , located in Tempe, Arizona (www.bngprodx.com). The agreement provides BNG the exclusive rights to sell the NOHO 2oz Shot throughout its nationwide retail stores as well as online sales through Amazon®.Our NOHO 2oz Shot will now be placed into the BNG sales engine, with the ability to be sold in national chains such as GNC and Vitamin Shoppe, in addition to independent smoke shops, vape shops and health stores. BNG's sales force will be putting the Shot into its national distribution in all major markets with concentration in California, New York and Florida.
Update 4/26/17 A/S reduced
https://wyobiz.wy.gov/Business/FilingDetails....1140218168
see Additional Details ; also, Update Restated Articles
NOHO, Inc. to Freeze Conversions and Negotiates Debt Buyout
https://finance.yahoo.com/news/noho-inc-freez...00170.html
PHOENIX, AZ--(Marketwired - Apr 24, 2017) - NOHO, Inc. ( OTC : DRNK ), a Wyoming corporation (the "Company" , announced the following:
The Company has reached an agreement in principle with its 95% majority convertible note holder for a moratorium on conversions, relating to notes issued after March 7, 2015.
In addition to freezing conversions, the Company will maintain its ability to retire the outstanding notes in cash.
If the notes subject to the freeze are not repurchased by the Company, the parties have agreed to a restriction of stock sales, subject to a lockdown and leakout agreement, which is currently being finalized.
David Mersky, NOHO's CEO, stated, "We have come to terms with our majority note holder to freeze conversions, which puts NOHO in a very strong position moving forward with significant developments underway. This is a strong signal of our majority debt holder's confidence in the long term vision we have for the Company. This agreement is also a big win for our shareholders, as we continue to make changes to reduce the outstanding shares and avoid dilution as a priority moving forward."
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM
